#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Mantle cell lymphoma recurrent Anal cancer recurrent Polymyositis Philadelphia positive chronic myeloid leukaemia Neuroendocrine carcinoma of the skin Familial hypertriglyceridaemia Systemic candida Fusarium infection Glioma Pituitary-dependent Cushing's syndrome Chronic graft versus host disease in liver Biotinidase deficiency Netherton's syndrome Autoimmune myositis Fibrosarcoma More trials…

    Learn about Rare Diseases

    MELAS syndrome – Treatment Kearns-Sayre syndrome – Diagnostics Leiomyosarcoma recurrent – Treatment Wiskott-Aldrich syndrome – Life with Disease Lymphatic malformation – Treatment CADASIL – Life with Disease Mantle cell lymphoma stage III – Basic Information Glomerulonephritis rapidly progressive – Trials in Disease Carcinoid syndrome – Life with Disease Ocular melanoma – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    ISPAGHULA HUSK Rosuvastatin Zinc Ribonucleic Acid AGALSIDASE BETA Dextromethorphan Hydrobromide Taldefgrobep Alfa Abt-494 Histidine SODIUM DIHYDROGEN PHOSPHATE Mometasone Furoate Ph. Eur. Amphotericine B, Liposome XMAB942 Darbepoetin Alfa Tecaginlimab Biotin Acetazolamide L-Acetylleucine Promazine Hydrochloride Repotrectinib Img-007 More therapies…

    Learn about Your Condition

    Hereditary optic atrophy Metastatic gastric cancer Alport's syndrome Micrographic skin surgery Desmoid tumour Cardiac arrest Haemophilia Dry mouth Gastric cancer Burkitt's lymphoma H1N1 influenza Primary biliary cholangitis Anal fissure Chondrosarcoma Paget's disease of the vulva More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Neuroendocrine tumour

  • Study on Retreatment with Lutetium (177Lu) Oxodotreotide for Patients with Intestinal Neuroendocrine Tumors

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Neuroendocrine tumour
    Investigated Drugs:
    • Lutetium (177Lu) Oxodotreotide
    • L-Arginine Hydrochloride
    • L-Lysine Hydrochloride
    France

  • Study on the Effect of Octreotide and Lanreotide in Peptide Receptor Radionuclide Therapy for Adults with Neuroendocrine Tumors

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Neuroendocrine tumour
    Investigated Drugs:
    • Lutetium (177Lu) Oxodotreotide
    • Lanreotide
    • Octreotide
    The Netherlands

  • Study on Continuing Somatostatin Analogues with Sunitinib, Octreotide, and Lutetium (177Lu) Oxodotreotide for Patients with Neuroendocrine Tumors

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Neuroendocrine tumour
    • Pancreatic neuroendocrine tumour
    • Gastroenteropancreatic neuroendocrine tumour disease
    Investigated Drugs:
    • Lutetium (177Lu) Oxodotreotide
    • Everolimus
    • Lanreotide
    Belgium The Netherlands

  • Study Comparing 177Lu-Edotreotide and Everolimus for Patients with Neuroendocrine Tumors in the Lung and Thymus

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Lutetium (177Lu) Edotreotide
    • Everolimus
    • L-Arginine Hydrochloride
    Belgium France Italy Spain

  • Study on Personalized vs Non-Personalized Radionuclide Therapy with 177Lu-Edotreotide and Capecitabine for Patients with Neuroendocrine Tumors

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Neuroendocrine tumour
    Investigated Drugs:
    • Lutetium (177Lu) Edotreotide
    • Capecitabine
    Sweden

  • Evaluation of V-Cu64 versus V-Ga68 PET-CT imaging in adults with diagnosed or suspected neuroendocrine tumors

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Neuroendocrine tumour
    Investigated Drugs:
    • Copper (64Cu) Chloride
    • Edotreotide
    • Gallium (68Ga) Chloride
    Poland
Previous Page
1 2 3 4
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!